Leadership Team and Board

Prof. Claude Wischik - Co-Founder, Chairman and Chief Executive

Professor Wischik is board-certified in psychiatry, professor of Old Age Psychiatry at the University of Aberdeen, Scotland. A pioneer in Tau research, he discovered the tau protein compositional structure of the Alzheimer’s tangles and established that it was possible to dissolve tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors.

Dr Richard G. Stefanacci – Chief Medical Officer

Dr Stefanacci is a practicing internist/geriatrician with a focus on care of persons with Alzheimer’s. He served as Health Policy Scholar for the Centers for Medicare & Medicaid Services (CMS) where his work focused on medication access and served on the Medicare Part D reg writing team. He has combined his expertise in healthcare policy in his teaching position at Thomas Jefferson University in their Jefferson College of Population Health. In his academic role he has well over 600 publications in addition to delivering well over 1000 lectures both nationally and internationally. Dr Stefanacci has achieved recognition as a fellow in both the College of Physicians of Philadelphia and American Geriatric Society as well as several national awards.

Dr Glenn Corr - Chief Operating Officer

Dr Corr has over 25 years’ experience in engineering, commercial and operational roles in high risk, capital intensive, industries. He has previously served as Operations Director of EnQuest, Asset and HSEQ Director, and Commercial Manager for Maersk, and a Principal Consultant at DNV. He holds a PhD in Systems Engineering, an MBA, and is a Fellow of the Institute of Directors. Currently Dr Corr is a board member of the Opportunity North-East (ONE) Life Sciences board.

Dr Charles Harrington - Chief Scientific Officer

Dr Harrington has extensive research experience in the field of neurodegenerative diseases and is author of more than 50 publications and co-inventor in 12 patent applications in this area. He has collaborated with Professor Wischik for over 20 years, developing assays for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease.

Prof. John Storey - Head of Technical

Professor Storey holds the Chair of Pharmaceutical Industrial Chemistry at University of Aberdeen and specialises in the area of synthetic organic chemistry with over 100 publications in this area. He has collaborated with Professor Wischik and Dr Charlie Harrington for 20 years and is co-inventor on 17 patent applications. Professor Storey heads a team of 26 research chemists with experience in synthesis and analytical chemistry. This team have synthesized TauRx’s portfolio of drug candidates and are responsible for their chemical scale-up, analysis, formulation and pipeline development.

Hwang Hong Wei - Finance Director

Mr Hwang is a member of the Institute of Certified Public Accountants of Singapore and joined TauRx Pharmaceuticals Ltd in March 2010. Previously, he was Finance Director of LexisNexis Asia and held senior positions in finance in the IT and financial industry. He holds a Bachelor of Accountancy (Honours) from the National University of Singapore and a Master of Science in CFO Leadership from the Singapore Management University.

Lawrence Wong Kin Meng - Company Secretary and Legal Advisor

Mr. Wong was called to the English Bar in 1983 as a Barrister and admitted to the Singapore Bar as an Advocate & Solicitor in 1984. He worked in several large and medium-sized law firms in Singapore, before establishing his own law firm in July 2000. Concurrently with his law practice, he holds appointments as a Notary Public and Commissioner for Oaths.

Tay Siew Choon - Deputy Chairman

Mr Tay has many years of experience in managing diverse technology businesses and was the COO of Singapore Technologies Pte Ltd. prior to his retirement in 2004. Holding a degree in electrical engineering and an MSc in systems engineering, he is also a board member at WisTa Laboratories Ltd. (a TauRx group company), Pan United Corporation Ltd. and Straco Corporation Ltd.

Dr Seng Shay Way - Managing Director

Dr Seng is a practising obstetrician, gynaecologist and reproductive specialist at Gleneagles Hospital, Singapore. He received his medical degree from the Royal College of Surgeons in Ireland and obtained his Masters in reproductive medicine from the University of New South Wales in Australia. He is currently the Medical director of Seng’s OG Practice Pte Ltd, a visiting IVF specialist at Raffles Hospital and board member of Age D'Or Healthcare Pte Ltd.

Professor Stephen Logan - Director

Professor Logan is the Chair of NHS Grampian having previously been Senior Vice-Principal of the University of Aberdeen where, as a neurophysiologist, his research interests were in the way the brain controls blood pressure, memory and appetite. He has published more than 100 scientific articles and has served on Research Council, Wellcome Trust and Health Department advisory panels. He is currently a board member of the Economic Development Organisation, Opportunity North East (ONE) where he chairs the Life Sciences Board and of WisTa Laboratories Ltd. and PoreDeen Pte Ltd (TauRx group companies).

Dr Sushilan Vasoo - Director

Dr Vasoo is an Associate Professorial Fellow in the Department of Social Work, National University of Singapore and an independent director of AEI Corporation. His research areas cover social issues in ageing. He is also a board member of WisTa Laboratories Ltd and PoreDeen Pte Ltd. (TauRx group companies) and was a Member of Parliament in the Government of Singapore from 1984 to 2001 and Chairman of the Government Parliamentary Committee for Community Development.

George Chia - Director

Mr Chia has been running his own paper business for 42 years. He is also a board member of WisTa Laboratories Ltd. and PoreDeen Pte. Ltd. (TauRx Group companies), and the Chairman of Premier Disposable Products Ltd (Hong Kong) and Guangdong Josco Disposable Product Ltd (China). Prior to his present appointment, he was Managing Director of Kookaburra Paper Products Pte. Ltd and Premier Paper Doyleys Pte. Ltd.

Paul Cheng - Director

Mr. Cheng is Managing Director and Head of Corporate Planning at DBS Bank where he is responsible for driving the bank’s merger and acquisition activities and strategic initiatives. Between 2012-14, he was also concurrently the Chief Operating Officer for DBS Group Finance. Prior to joining DBS, Paul worked with the Monetary Authority of Singapore, Temasek Holdings and the Government of Singapore Investment Corporation. Paul graduated from Nanyang Technological University, Singapore and has been a Certified Public Accountant since 2000.

Tan Sri Lim Kok Thay - Director

Tan Sri Lim Kok Thay is the Chairman and Chief Executive of Genting Berhad, the ultimate holding company of the Genting Group, and has served in various positions within the Genting Group since 1976. He holds a Bachelor of Science in Civil Engineering from the University of London, UK, and attended the Programme for Management Development of Harvard Business School, Harvard University, USA. He is also a Visiting Professor in the Department of Electrical and Electronic Engineering, Imperial College, London, UK and an Honorary Professor of Xiamen University, China.

Tan Kong Han - Director

Mr Tan is the President and Chief Operating Officer and Executive Director of Genting Berhad as well as Chief Executive and Executive Director of Genting Plantations Berhad. He read economics and laws and has been conferred a Master of Arts by University of Cambridge. He was called to the English Bar (Lincoln’s Inn) in 1989 and the Malaysian Bar in 1990. He worked in investment banking prior to joining Tanjong Public Limited Company (“Tanjong”) as the Group Chief Operating Officer in 2003 and left Tanjong in 2007 to join Genting.

Ms. Tang Jialei - Director

Ms Tang Jialei serves as director at her family office, engaging in projects of varying scales including acquisition of listed companies, hospitality portfolios, fund set-ups and brand architecture. She cares deeply about the sustainability and impact of investments, demonstrated in her inputs to the subsidiaries’ operations. Her investment experience is international and spans across industries including real estate, hospitality, education, technology and pharmaceutical in Chinese, South East Asian, American, European, and Australian markets. Her academic background is in architectural design and philosophy.

Goh Chung Meng (Alternate Director to Tay Siew Choon) - Corporate Fundraising Team

Mr Goh is currently a Director of AVI-TECH Electronics Ltd. Prior to his present appointment, Mr Goh held senior positions in Deloitte & Touche Management Consultants, Carr Indosuez Asia (Merchant Banking unit of Credit Agricole) and Suez Asia Holdings (an Asian private equity fund). From 2001 to 2008, Mr Goh served as a Panel Member of a Singapore government innovation and research fund, The Enterprise Challenge Unit (TEC), PS 21 Office, Public Service Division, Prime Minister's Office. Mr Goh graduated from the NUS Business School, National University of Singapore with a Bachelor of Business Administration (BBA).

Dr Loh Yin Sze (Alternate Director to Dr Seng Shay Way) - Corporate Fundraising Team

Dr Loh graduated from the National University of Singapore with a Bachelor of Medicine and Bachelor of Surgery and did her clinical rotations in Singapore. She also trained in molecular biology basic research. In 2004, Dr Loh was awarded the NUS-NUH Annual Meeting “Young Doctor Award” for her research work in the field of discovery of novel therapeutics. Dr Loh has also worked as a Financial Research Analyst covering the healthcare, biomedical and pharmaceutical sectors when she was employed at Philip Securities Pte Ltd.

Mr Lin Daqi (Alternate Director)

Mr Daqi is an Investment Manager with Haiyi Holdings Pte Ltd. He is responsible for the origination, evaluation, structuring and execution of investments across industries and geographies. He started his career in the financial industry in 2009 and had served in various capacities within the Strategic Advisory and Mergers & Acquisitions team within DBS. His key directorships include ARA US Hospitality Trust, Non-Independent Non-Executive Director (Since Jan 2020) and WhiteCoat Global, Director (Since Mar 2021).

Back to About Us